| First Author | Kong Y | Year | 2024 |
| Journal | ACS Chem Neurosci | Volume | 15 |
| Issue | 11 | Pages | 2112-2120 |
| PubMed ID | 38776461 | Mgi Jnum | J:360710 |
| Mgi Id | MGI:7787187 | Doi | 10.1021/acschemneuro.4c00067 |
| Citation | Kong Y, et al. (2024) Increased Cerebral Level of P2X7R in a Tauopathy Mouse Model by PET Using [(18)F]GSK1482160. ACS Chem Neurosci 15(11):2112-2120 |
| abstractText | Neuroinflammation plays an important role in Alzheimer's disease and primary tauopathies. The aim of the current study was to map [(18)F]GSK1482160 for imaging of purinergic P2X7R in Alzheimer's disease and primary tauopathy mouse models. Small animal PET was performed using [(18)F]GSK1482160 in widely used mouse models of Alzheimer's disease (APP/PS1, 5xFAD, and 3xTg), 4-repeat tauopathy (rTg4510) mice, and age-matched wild-type mice. Increased uptake of [(18)F]GSK1482160 was observed in the brains of 7-month-old rTg4510 mice compared to wild-type mice and compared to 3-month-old rTg4510 mice. A positive correlation between hippocampal tau [(18)F]APN-1607 and [(18)F]GSK1482160 uptake was found in rTg4510 mice. No significant differences in the uptake of [(18)F]GSK1482160 was observed for APP/PS1 mice, 5xFAD mice, or 3xTg mice. Immunofluorescence staining further indicated the distribution of P2X7Rs in the brains of 7-month-old rTg4510 mice with accumulation of tau inclusion. These findings provide in vivo imaging evidence for an increased level of P2X7R in the brains of tauopathy mice. |
